Evidence map›Paper›PMID 37098055›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2023

Self-assembling paclitaxel-mediated stimulation of tumor-associated macrophages for postoperative treatment of glioblastoma.

Feihu Wang, Qian Huang, Hao Su, Mingjiao Sun, Zeyu Wang, Ziqi Chen, Mengzhen Zheng, Rami W Chakroun, Maya K Monroe, Daiqing Chen and 10 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Dichotomous role of CD47-SIRPActa pharmaceutica Sinica. B · 2026
    Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Construction of a localized immune nicheActa pharmaceutica Sinica. B · 2026
    Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 1 institution in 1 country.

Feihu WangDepartment of Chemical and Biomolecular Engineering, Whiting School of Engineering, The Johns Hopkins University, Baltimore, MD 21218.ORCID 0000-0002-0358-967X
Qian HuangDepartment of Anesthesiology and Critical Care Medicine, School of Medicine, The Johns Hopkins University, Baltimore, MD 21205.ORCID 0000-0001-6039-103X
Hao SuDepartment of Chemical and Biomolecular Engineering, Whiting School of Engineering, The Johns Hopkins University, Baltimore, MD 21218.
Mingjiao SunDepartment of Chemical and Biomolecular Engineering, Whiting School of Engineering, The Johns Hopkins University, Baltimore, MD 21218.ORCID 0000-0001-9497-4903
Zeyu WangDepartment of Chemical and Biomolecular Engineering, Whiting School of Engineering, The Johns Hopkins University, Baltimore, MD 21218.
Ziqi ChenDepartment of Chemical and Biomolecular Engineering, Whiting School of Engineering, The Johns Hopkins University, Baltimore, MD 21218.
Mengzhen ZhengDepartment of Chemical and Biomolecular Engineering, Whiting School of Engineering, The Johns Hopkins University, Baltimore, MD 21218.
Rami W ChakrounDepartment of Chemical and Biomolecular Engineering, Whiting School of Engineering, The Johns Hopkins University, Baltimore, MD 21218.
Maya K MonroeDepartment of Chemical and Biomolecular Engineering, Whiting School of Engineering, The Johns Hopkins University, Baltimore, MD 21218.ORCID 0000-0002-8161-5298
Daiqing ChenCenter for Nanomedicine, Wilmer Eye Institute, School of Medicine, The Johns Hopkins University, Baltimore, MD 21231.
Zongyuan WangDepartment of Chemical and Biomolecular Engineering, Whiting School of Engineering, The Johns Hopkins University, Baltimore, MD 21218.ORCID 0000-0002-8217-0307
Noah GorelickDepartment of Neurosurgery, School of Medicine, The Johns Hopkins University, Baltimore, MD 21231.
Riccardo SerraDepartment of Neurosurgery, School of Medicine, The Johns Hopkins University, Baltimore, MD 21231.
Han WangDepartment of Chemical and Biomolecular Engineering, Whiting School of Engineering, The Johns Hopkins University, Baltimore, MD 21218.
Yun GuanDepartment of Anesthesiology and Critical Care Medicine, School of Medicine, The Johns Hopkins University, Baltimore, MD 21205.ORCID 0000-0003-1321-6655
Jung Soo SukDepartment of Chemical and Biomolecular Engineering, Whiting School of Engineering, The Johns Hopkins University, Baltimore, MD 21218.
Betty TylerDepartment of Neurosurgery, School of Medicine, The Johns Hopkins University, Baltimore, MD 21231.
Henry BremDepartment of Neurosurgery, School of Medicine, The Johns Hopkins University, Baltimore, MD 21231.ORCID 0000-0001-7539-4786
Justin HanesDepartment of Chemical and Biomolecular Engineering, Whiting School of Engineering, The Johns Hopkins University, Baltimore, MD 21218.
Honggang CuiDepartment of Chemical and Biomolecular Engineering, Whiting School of Engineering, The Johns Hopkins University, Baltimore, MD 21218.ORCID 0000-0002-4684-2655
Johns Hopkins University · US

Funding

Birth Tissue Products for Non-opioid Treatment of Post-surgical PainR01NS117761 · NINDS · JOHNS HOPKINS UNIVERSITY · PI GUAN, YUN · 2020 to 2024
$2.6M
Mechanistic Study of Pain Inhibition by Activation of Non-nociceptive Afferent FibersR01NS110598 · NINDS · JOHNS HOPKINS UNIVERSITY · PI GUAN, YUN · 2019 to 2024
$2.4M
NINDS NIH HHS R01 NS110598NINDS NIH HHS R01 NS117761
6 · The paper itself

Abstract

The unique cancer-associated immunosuppression in brain, combined with a paucity of infiltrating T cells, contributes to the low response rate and poor treatment outcomes of T cell-based immunotherapy for patients diagnosed with glioblastoma multiforme (GBM). Here, we report on a self-assembling paclitaxel (PTX) filament (PF) hydrogel that stimulates macrophage-mediated immune response for local treatment of recurrent glioblastoma. Our results suggest that aqueous PF solutions containing aCD47 can be directly deposited into the tumor resection cavity, enabling seamless hydrogel filling of the cavity and long-term release of both therapeutics. The PTX PFs elicit an immune-stimulating tumor microenvironment (TME) and thus sensitizes tumor to the aCD47-mediated blockade of the antiphagocytic "don't eat me" signal, which subsequently promotes tumor cell phagocytosis by macrophages and also triggers an antitumor T cell response. As adjuvant therapy after surgery, this aCD47/PF supramolecular hydrogel effectively suppresses primary brain tumor recurrence and prolongs overall survivals with minimal off-target side effects.

Indexed as

Brain NeoplasmsGlioblastomaCell Line, TumorHumansHydrogelsImmunotherapyNeoplasm Recurrence, LocalPaclitaxelTumor-Associated MacrophagesTumor MicroenvironmentHydrogelsPaclitaxelcancerchemotherapyhydrogelimmunotherpayself-assembly

Identifiers

PMID37098055
PMCPMC10161130
OpenAlexW4366981339

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.